204 related articles for article (PubMed ID: 30535494)
1. Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.
Thomas NA; Abraham RG; Dedi B; Krucher NA
Int J Oncol; 2019 Feb; 54(2):527-536. PubMed ID: 30535494
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
3. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
5. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
[TBL] [Abstract][Full Text] [Related]
6. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
7. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
[TBL] [Abstract][Full Text] [Related]
8. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Conradt L; Godl K; Schaab C; Tebbe A; Eser S; Diersch S; Michalski CW; Kleeff J; Schnieke A; Schmid RM; Saur D; Schneider G
Neoplasia; 2011 Nov; 13(11):1026-34. PubMed ID: 22131878
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
10. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
11. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Miyabayashi K; Ijichi H; Mohri D; Tada M; Yamamoto K; Asaoka Y; Ikenoue T; Tateishi K; Nakai Y; Isayama H; Morishita Y; Omata M; Moses HL; Koike K
Cancer Res; 2013 Apr; 73(7):2221-34. PubMed ID: 23378339
[TBL] [Abstract][Full Text] [Related]
13. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD
Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931
[TBL] [Abstract][Full Text] [Related]
14. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Zhang D; Li L; Jiang H; Knolhoff BL; Lockhart AC; Wang-Gillam A; DeNardo DG; Ruzinova MB; Lim KH
Clin Cancer Res; 2017 Apr; 23(7):1748-1759. PubMed ID: 27702822
[No Abstract] [Full Text] [Related]
15. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Jagadeeshan S; Subramanian A; Tentu S; Beesetti S; Singhal M; Raghavan S; Surabhi RP; Mavuluri J; Bhoopalan H; Biswal J; Pitani RS; Chidambaram S; Sundaram S; Malathi R; Jeyaraman J; Nair AS; Venkatraman G; Rayala SK
Ann Oncol; 2016 Aug; 27(8):1546-56. PubMed ID: 27117533
[TBL] [Abstract][Full Text] [Related]
16. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
18. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.
Li H; Zhou W; Li L; Wu J; Liu X; Zhao L; Jia L; Sun Y
Neoplasia; 2017 Jun; 19(6):509-518. PubMed ID: 28535453
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Solca F; Modjtahedi H
Int J Oncol; 2016 Mar; 48(3):908-18. PubMed ID: 26781210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
